Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This study aims to determine: a) whether those patients with 'low level' viral load results
(between 200 and 3,000 copies/ml) could be monitored as opposed to starting preemptive
therapy with valganciclovir, ganciclovir and/or foscarnet; b) whether those patients with
'high level' viral load results (above 3,000 copies/ml) could stop preemptive therapy
earlier, thus maximising the benefits of therapy and minimising its risks.